Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 8 to 9 directors, adding Menassie Taddese effective November 2, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 8 to 9 directors, adding Menassie Taddese effective November 2, 2026
- Taddese brings Pfizer and Viatris emerging-markets and finance experience, potentially supporting international growth strategy
- Audit Committee appointment, with Nasdaq and Exchange Act independence qualification
- Initial equity award valued at approximately $450,000, creating shareholder dilution and onboarding compensation
- Future annual equity grants targeted at approximately $300,000, vesting subject to continued board service
Item 7.01 · Regulation FD Disclosure
- Taddese appointed to Xeris Biopharma’s Board of Directors
- Board refresh may influence governance, strategic oversight and shareholder confidence
- Appointment details and rationale provided in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Menassie M. Taddese appointed director effective November 2, 2026
- Audit Committee appointment strengthens board financial oversight and governance expertise
- Former Viatris Emerging Markets president, overseeing an approximately $3 billion business across more than 125 markets
- Board addition supports commercial portfolio growth and advancement of Phase 3-ready XP-8121
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.